BCL2 and acute myeloid leukemia: For example, they demonstrated that the Bcl-2 inhibitor venetoclax and the pan histone deacetylase (HDAC) inhibitor panobinostat exhibited potent activities against less-differentiated and more-differentiated AML states respectively [3,4].